1. OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. (21st January 2022) Authors: Alexander, J; Kennedy, N; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Castro Seoane, R; Liu, Z; Nice, R; Bewshea, C; D'Mello, A; Constable, L; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P M; Hicks, L; Williams, H; Kent, A; Linger, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i022 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy. (30th January 2023) Authors: Liu, Z; Alexander, J; Le, K; Zhou, X; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Lin, K; Mcfarlane, L; Anand, N; Constable, L; Castro-Seoane, R; Nice, R; Bewshea, C; D'Mello, A; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗